Clinical Trials Logo

TN ER-/PR-/HER2- Breast Cancer clinical trials

View clinical trials related to TN ER-/PR-/HER2- Breast Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT03981705 Active, not recruiting - Clinical trials for Triple Negative Breast Cancer

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Start date: August 8, 2019
Phase:
Study type: Observational

This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.